Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial.

Monomorphic ventricular tachycardia PCI STEMI Ventricular arrhythmias Ventricular fibrillation

Journal

Heart rhythm O2
ISSN: 2666-5018
Titre abrégé: Heart Rhythm O2
Pays: United States
ID NLM: 101768511

Informations de publication

Date de publication:
Mar 2023
Historique:
medline: 31 3 2023
entrez: 30 3 2023
pubmed: 31 3 2023
Statut: epublish

Résumé

Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia. We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing. The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry. Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01-6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90-15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68-14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality. VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance.

Sections du résumé

Background UNASSIGNED
Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia.
Objective UNASSIGNED
We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing.
Methods UNASSIGNED
The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry.
Results UNASSIGNED
Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01-6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90-15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68-14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality.
Conclusion UNASSIGNED
VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance.

Identifiants

pubmed: 36993916
doi: 10.1016/j.hroo.2022.12.008
pii: S2666-5018(22)00357-9
pmc: PMC10041082
doi:

Types de publication

Journal Article

Langues

eng

Pagination

200-206

Informations de copyright

© 2022 Heart Rhythm Society. Published by Elsevier Inc.

Références

Europace. 2014 Dec;16(12):1759-66
pubmed: 25100756
Am J Cardiol. 2022 Jan 15;163:13-19
pubmed: 34774287
Am J Cardiol. 2015 Feb 15;115(4):417-22
pubmed: 25549882
Eur Heart J Acute Cardiovasc Care. 2012 Dec;1(4):302-11
pubmed: 24062921
Am J Cardiol. 1998 Aug 1;82(3):265-71
pubmed: 9708651
Am J Cardiol. 2017 Nov 15;120(10):1755-1760
pubmed: 28867126
N Engl J Med. 2017 Sep 21;377(12):1132-1142
pubmed: 28844201
Am J Med. 2008 Sep;121(9):797-804
pubmed: 18724970
J Am Coll Cardiol. 2008 Feb 5;51(5):546-51
pubmed: 18237683
JAMA. 2009 May 6;301(17):1779-89
pubmed: 19417195
Heart Rhythm. 2018 Jun;15(6):822-829
pubmed: 29454138
Eur Heart J. 2014 Jan;35(2):116-22
pubmed: 24258072
J Electrocardiol. 2007 Jan;40(1):72-7
pubmed: 17070829
Am J Cardiol. 2015 Sep 1;116(5):678-85
pubmed: 26150175
Circulation. 1998 Dec 8;98(23):2567-73
pubmed: 9843464
J Am Coll Cardiol. 2004 May 19;43(10):1765-72
pubmed: 15145097
Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):16-23
pubmed: 25114328
Am Heart J. 2016 May;175:36-46
pubmed: 27179722
Circ Cardiovasc Interv. 2021 Dec;14(12):e008969
pubmed: 34903034
Am Heart J. 2019 Feb;208:1-10
pubmed: 30471486

Auteurs

Marina M Demidova (MM)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Rebecca Rylance (R)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Sasha Koul (S)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Christian Dworeck (C)

Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden.

Stefan James (S)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Mikael Aasa (M)

Department of Cardiology, Södersjukhuset, Stockholm, Sweden.

Mehmet Hamid (M)

Department of Cardiology, Mälarsjukhuset, Eskilstuna, Sweden.

Eva Swahn (E)

Department of Cardiology, Linköping University Hospital, Linköping, Sweden.

Kristina Hambraeus (K)

Department of Cardiology, Falun Hospital, Falun, Sweden.

Mikael Danielewicz (M)

PCI-Unit, Karlstad Hospital, Karlstad, Sweden.

Rikard Linder (R)

Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.

Ole Fröbert (O)

Department of Cardiology, Faculty of Health, Örebro University, Örebro, Sweden.

Per Grimfjärd (P)

Department of Internal Medicine, Västmanlands Hospital, Västerås, Sweden.

Jason Stewart (J)

Department of Cardiology, Skaraborgs Hospital, Skövde, Sweden.

Loghman Henareh (L)

Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Jonas Andersson (J)

Department of Cardiology, Umeå University, Umeå, Sweden.

Henrik Wagner (H)

Department of Cardiology, Helsingborg Hospital, Helsingborg, Sweden.

David Erlinge (D)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Pyotr G Platonov (PG)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Classifications MeSH